Diabetes News and Research

Latest Diabetes News and Research

ConjuChem Biotechnologies completes non-dilutive capital transaction

ConjuChem Biotechnologies Inc. ("ConjuChem") (TSX:CJB) today announced the completion of the transaction providing $5 million in new, non-dilutive capital to the Company. The Superior Court of Québec has approved the previously announced plan of arrangement (the "Arrangement") under section 192 of the Canada Business Corporations Act (the "CBCA") involving ConjuChem and Colabor Income Fund ("Colabor"), among others, all as fully described in ConjuChem's management information circular dated July 17, 2009.

26 Aug 2009

Study reveals benefits of balloon dilation to heart patients with moderately impaired renal function

People with kidney disease undergo balloon dilation treatment after myocardial infarction less frequently, and therefore have a poorer prognosis. This according to new clinical research published in the journal Circulation.

26 Aug 2009

Clinical study results of USANA Health Sciences products published in the Obesity and Weight Management journal

USANA Health Sciences, Inc. announced today that results of a large, third-party clinical study involving USANA products, conducted at the University of Colorado Denver (UCD), have been published in the August 2009 edition of the journal Obesity and Weight Management.

26 Aug 2009

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Amgen today announced that in a large, randomized, double-blind, placebo-controlled, Phase 3 study of patients with chronic kidney disease (CKD) (not requiring dialysis), anemia and type-2 diabetes (the Trial to Reduce Cardiovascular Endpoints with Aranesp((R)) Therapy, or TREAT), treatment of anemia with Aranesp((R) )(darbepoetin alfa) to a hemoglobin target of 13 g/dL had no statistically significant effect on either of two primary endpoints compared with placebo treatment.

26 Aug 2009

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

Dainippon Sumitomo Pharma Co., Ltd., (DSP) announced today positive results from PEARL 2 - a phase 3 clinical trial of lurasidone for the treatment of patients with schizophrenia. In this trial, both lurasidone 40 and 120 mg/day were significantly more effective than placebo for the treatment of schizophrenia. Lurasidone was well-tolerated with an overall discontinuation rate that was similar to placebo.

26 Aug 2009

New online educational forum for medical professionals from HMP Communications

HMP Communications, the authoritative source for education services targeting healthcare professionals for over two decades, announced it has added a new online educational forum at www.CardiovascularLIVE.com. The site offers video instruction and discussion forums for medical professionals.

26 Aug 2009

Research study concludes the difference in mortality between men and women depending on the type of ACS

A new study from NYU School of Medicine found that women may have a slightly higher risk of death than men in the thirty days following an acute coronary syndrome (ACS), but that these differences appear to be attributable to factors such as severity and type of ACS.

26 Aug 2009

Virginia Tech researchers to help pre-diabetic adults begin resistance training for preventing diabetes

Systematic, progressive resistance training - also called strength training - is a safe and efficient way for middle-aged and older adults to improve their health. A Virginia Tech led research team that includes experts in behavior, exercise, physiology, and medicine is designing a program to help pre-diabetic adults begin and, most important, maintain resistance training in order to prevent diabetes.

26 Aug 2009

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Results of the Phase III RE-LY(R) (Randomized Evaluation of Long-Term Anticoagulant Therapy, Warfarin, Compared to Dabigatran) study will be presented at the European Society of Cardiology (ESC) Congress in Barcelona on Sunday, Aug. 30. The primary objective of RE-LY was to assess the safety and efficacy of the investigational oral direct thrombin inhibitor, dabigatran etexilate, against the current standard therapy, warfarin, for the prevention of stroke in patients with atrial fibrillation (AF).

26 Aug 2009

Racial/ethnic disparities in clinically confirmed outcomes of heart and stroke surgeries

Minorities have poorer results and higher rates of unnecessary surgery from a common procedure used to remove plaque from inside the carotid artery, according to a UT Southwestern Medical Center doctor who is lead author of the study in the journal Stroke.

26 Aug 2009

Women face higher risk of mortality rate following acute coronary syndromes

Women may have a slightly higher risk of death than men in the 30 days following an acute coronary syndrome (ACS; such as heart attack or unstable angina), but this difference appears attributable to factors such as severity and type of ACS, clinical differences and angiographic severity according to a study in the August 26 issue of JAMA.

26 Aug 2009

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Alvine Pharmaceuticals, Inc. today announced that patient enrollment has begun in a Phase 2a, randomized, double-blind, placebo-controlled study to assess the safety and efficacy of ALV003 for use in the treatment of celiac disease.

26 Aug 2009

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

Obesity is on a rampage, with the World Health Organization pegging the numbers at more than 300 million worldwide, with a billion more overweight. With obesity comes the increased risk for cardiovascular disease, Type II diabetes, and hypertension.

25 Aug 2009

Medtronic's Q1 financial results announced

Medtronic, Inc. (NYSE:MDT) today announced financial results for its first quarter of fiscal year 2010, which ended July 31, 2009.

25 Aug 2009

Seechange Health acquires Central Benefits National Life Insurance company

SeeChange Health, the nation’s only fully-insured, value-based health insurance provider, announced today the acquisition of Central Benefits National Life Insurance, a health and life insurance company based in Westerville, OH. The transaction closed on July 31, 2009.

25 Aug 2009

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

Salix Pharmaceuticals, Ltd. (NASDAQ:SLXP) today announced the Food and Drug Administration (FDA) has accepted for filing and designated for Priority Review the Company’s New Drug Application (NDA) for rifaximin tablets 550 mg for the maintenance of remission of hepatic encephalopathy (HE). Additionally, the FDA has informed the Company of its plan to schedule an Advisory Committee meeting in late February 2010 to discuss the application.

25 Aug 2009

PediaVision device to detect eye disorders in autistic children

PediaVision, a company dedicated to solving the critical problem of undiagnosed vision problems affecting thousands of children, today announced a breakthrough in the use of the PediaVision Assessment Solution for autistic children.

25 Aug 2009

Karo Bio collaborates with Wyeth for treating inflammatory diseases

The Swedish biotech company Karo Bio today announced that beginning September 1, 2009, Wyeth will take on all future research and development activities under the drug discovery collaboration between the parties.

25 Aug 2009

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Mild glucose intolerance in pregnancy may be an early identifier of women who are at increased risk of heart disease in the future, found a new study http://www.cmaj.ca/press/cmaj090569.pdf published in CMAJ (Canadian Medical Association Journal) www.cmaj.ca.

25 Aug 2009

Pharmacy Times serves as a go-to resource for pharmacists on OTC products

Consumers overwhelmed by options when considering over-the-counter (OTC) medications can now find out which products are most recommended by pharmacists through Pharmacy & Healthcare Communications' OTC Recommendations Survey.

25 Aug 2009

Diabetes News and Research

Latest Diabetes News and Research

ConjuChem Biotechnologies completes non-dilutive capital transaction

Study reveals benefits of balloon dilation to heart patients with moderately impaired renal function

Clinical study results of USANA Health Sciences products published in the Obesity and Weight Management journal

Patients enrolled in the TREAT Phase 3 study treated with Aranesp to a target hemoglobin of 13 g/dL

Positive results obtained from phase 3 clinical trial of lurasidone for treating schizophrenia

New online educational forum for medical professionals from HMP Communications

Research study concludes the difference in mortality between men and women depending on the type of ACS

Virginia Tech researchers to help pre-diabetic adults begin resistance training for preventing diabetes

Phase III RE-LY study results to be presented at the European Society of Cardiology Congress

Racial/ethnic disparities in clinically confirmed outcomes of heart and stroke surgeries

Women face higher risk of mortality rate following acute coronary syndromes

Alvine Pharmaceuticals commences Phase 2a clinical trial to evaluate the efficacy of ALV003

Studies reveal that obese people are at greater risk for developing Alzheimer's disease

Medtronic's Q1 financial results announced

Seechange Health acquires Central Benefits National Life Insurance company

FDA accepts for filing Salix Pharmaceuticals' NDA for rifaximin tablets

PediaVision device to detect eye disorders in autistic children

Karo Bio collaborates with Wyeth for treating inflammatory diseases

New study reveals that mild glucose intolerance in pregnancy may relate to risk of heart disease

Pharmacy Times serves as a go-to resource for pharmacists on OTC products

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Diabetes News and Research

Latest Diabetes News and Research

Innovation in neuroscience drug discovery - eBook eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in